PRESS RELEASE
News
-
-
PRESS RELEASE
ProCredit group ends 2025 with strong loan growth and digital retail banking transformation in full momentum; financial results reflect strategic transition
ProCredit group ends 2025 with strong loan growth and digital retail banking transformation momentum. Strategy execution advancing with 7.8% RoE in line with guidance -
-
-
PRESS RELEASE
Helvetica Swiss Commercial Fund confirms strong earnings quality and achieves attractive investment and dividend returns
Helvetica Swiss Commercial Fund reports strong earnings quality and attractive investment returns in 2025. Achieved 6.57% ROI and 5% distribution yield with 95.7% occupancy rate -
PRESS RELEASE
Helvetica Swiss Commercial Fund confirme l’excellente qualité de ses résultats et réalise des rendements attractifs des placements et des dividendes
Helvetica Swiss Commercial Fund annonce des résultats annuels solides en 2025 avec des rendements attractifs sur les placements et les dividendes, soulignant sa position forte sur le marché suisse de l'immobilier commercial -
PRESS RELEASE
Helvetica Swiss Living Fund clôture avec succès sa phase d’optimisation stratégique avec un excellent résultat annuel 2025 et se concentre sur la création de valeur supplémentaire dans le portefeuille
Le Helvetica Swiss Living Fund clôture l'exercice 2025 avec succès, affichant un rendement de 4.68%, une distribution stable et des revenus stables grâce à des ajustements stratégiques -
PRESS RELEASE
Helvetica Swiss Living Fund concludes its successful strategic optimization phase with a strong annual result for 2025 and focuses on further value creation in the portfolio
Helvetica Swiss Living Fund concludes successful strategic optimization phase with strong annual results for 2025, focusing on further value creation in the portfolio -
PRESS RELEASE
Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer
Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer -
